We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Verona Pharma Plc | LSE:VRP | London | Ordinary Share | GB00BYW2KH80 | ORD 5P |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
45.00 | 65.00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
- |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
- | O | 0 | 55.00 | GBX |
Verona Pharma (VRP) Share Charts1 Year Verona Pharma Chart |
|
1 Month Verona Pharma Chart |
Intraday Verona Pharma Chart |
Date | Time | Title | Posts |
---|---|---|---|
02/2/2024 | 09:32 | Verona Pharma: Developing first in class drugs for respiratory diseases | 1,556 |
30/10/2018 | 08:41 | Still time to look at Verona Pharma (VRP) | - |
01/8/2018 | 10:42 | Verona Pharma (VRP) One to Watch | - |
16/2/2015 | 17:30 | Verona Pharma with Charts & News | 11,549 |
24/11/2011 | 12:54 | verona pharma | 173 |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|
Top Posts |
---|
Posted at 01/1/2024 22:50 by haroldthegreat thank you Tim for the share chart. |
Posted at 09/5/2023 11:44 by tradertrev Cash and equivalents have risen from the $285m (pro-forma that included ATM issuance up to 3rd March 2023) at 31st December 2022, to $291m as at 31st March 2023. This suggests that further ATM issuance of $6m above Q2 cash costs (i.e. a total of $20m, or roughly 1m ADRs) were issued under the ATM facility between 3rd and 31st March 2023.This could explain some relative sluggishness in the share price over that period. There is no mention of ATM issuance in today's statement in relation to both the total cash and equivalents and the liquidity available to last until at least the end of 2025. This suggests to me that they may have stopped issuing further shares under the ATM facility, at least for the time being. This could help the shares move on a bit. |
Posted at 07/2/2023 07:04 by tradertrev The graph shows that the price has fallen back after a barnstormingly good year. Yesterday's rise is very close to breaking the short term downtrend.Don't understand your unchanged expectations Haff. Maybe holding the chart the right way up would help? |
Posted at 06/2/2023 09:58 by haff1 Not good from a TA perspective: lowering highs and lowering lows....the graph is indicating a fall!! So no change in VRP expectaions.... |
Posted at 22/12/2022 14:31 by timbo003 >>>joeblog, I don't really know the answer to that one.I am at last up on this one, albeit not by much, my average buy price was around 2.2p/share (pre-consolidation) most of which were acquired in the 2014 open offer. I'm a bit annoyed with myself for not topping after the first phase III results (ENHANCE2) as those results were truely exceptional, I suspect the shares have further to run, especially in the lead up to news regarding FDA and EMA approval (with a truely differentiated label) - which now seems rather likely, but I think I will just stick with what I have got for now (having missed the obvious time to top up after ENHANCE2) |
Posted at 22/12/2022 11:21 by timbo003 Your recollection is spot on TradertrevHere is the historical chart up to the delisting on Aim and a table to show the price equivalents of the old pre-consolidation shares, the post-consolidation shares and the ADRs |
Posted at 22/12/2022 08:53 by tradertrev Harold - not hard facts, but I seem to recall that if you went back far enough on old UK charts you would see the equivalent of at least £20 per UK share. This was diluted many times by share issuance at ever decreasing prices. £20 per UK share would be the equivalent now of $133 per ADR (8 shares per ADR), although at more normal exchange rates back then (say $1.50) it would be more like $107.I suspect this is all rather academic however. |
Posted at 20/12/2022 23:59 by haroldthegreat what was the highest price achieved per share in uk prior to us listing ? |
Posted at 20/12/2022 10:59 by timbo003 I'll settle for that, not quite as good as ENHANCE2, as they just missed out on significance for reduction in exacerbation rate, but they are good enough, especially when you combine the data from the two studies and bingo, Clinically menaingful statistical significant reductions in exacerbations which everway you look at itI predict a blue day for the share price |
Posted at 09/8/2022 19:48 by haroldthegreat Tim perhaps you should remove the LSE VRP charts ? Looks like that the shares have flat lined . Today they have been given a shot of Viagra but like Viagra the effect on the share price is waning after a few hours ! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions